EXAS vs UTHR · rev $2.76B vs P/E 20, rev $1.56B
EXACT Sciences Corporation (EXAS) versus United Therapeutics Corporation (UTHR) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
United Therapeutics Corporation (UTHR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported UTHR revenue for 2026-06-30 was $1.56B. Net income was $607.9M. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
EXAS currently screens at market cap $20.03B. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
Not investment advice. Open the EXAS and UTHR stock pages for the full models.
Not investment advice.